Semaglutide is a medicine that copies one of your body's own appetite hormones. Technically it's a GLP-1 receptor agonist — a mouthful that just means "a molecule that switches on the same receptor the gut hormone GLP-1 uses." Unlike most peptides on this site, semaglutide is a fully approved medicine with a very large human trial record.
In plain terms: it borrows a natural "I'm full" signal and makes it last far longer than nature does.
How it works
After you eat, your gut releases GLP-1, a hormone that tells your body to release insulin, slow down how fast the stomach empties, and feel full sooner. The problem for drug-makers: natural GLP-1 vanishes within minutes. Semaglutide is a redesigned version that does the same job but survives in the body for about a week1. The full mechanism is in the GLP-1 explainer.
Why once a week
The trick that makes weekly dosing possible is albumin binding. Semaglutide carries a fatty-acid chain that latches onto albumin, an abundant, long-lasting blood protein. Hitched to albumin, the drug is shielded from rapid breakdown, so its half-life stretches to roughly 7 days1. Because doses repeat before the last one clears, levels build up over the first month or so to a steady plateau.
More on this in why GLP-1 medications are weekly and how long semaglutide stays in your system.
What the trials actually found
This is where semaglutide stands apart from research peptides: it has been tested in large, rigorous human trials, and the evidence has built up over time:
| Trial | People | Key result | Year |
|---|---|---|---|
| STEP 12 | 1,961 adults with obesity, no diabetes | Average ~14.9% body-weight loss over 68 weeks; 86% lost ≥5% | 2021 |
| SELECT3 | ~17,600 adults, obesity + heart disease, no diabetes | 20% fewer major cardiovascular events (heart attack, stroke, CV death): 6.5% vs 8.0% | 2023 |
In plain terms: STEP 1 showed the average person lost close to a sixth of their body weight — a result that reshaped the field. Then SELECT showed something bigger still: semaglutide didn't just reduce weight, it cut the rate of heart attacks and strokes by about a fifth in high-risk people — the first weight medicine ever proven in a rigorous trial to do so3. (Separate SUSTAIN diabetes trials showed blood-sugar benefits.)
The brand names
The same molecule is sold under different names for different approved uses:
- Ozempic — semaglutide for type 2 diabetes (injection)
- Wegovy — semaglutide for weight management (injection)
- Rybelsus — semaglutide in a daily tablet
They are the same active compound; the brand reflects the product and its approval, not a different drug — see Ozempic vs Wegovy vs Mounjaro vs Zepbound.
How it compares
The headline peer comparison is single- versus dual-receptor: semaglutide hits one incretin receptor, while tirzepatide hits two (semaglutide vs tirzepatide).
Latest research (2023–2025)
- SELECT (2023) was the big one: in ~17,600 people with obesity and heart disease, semaglutide cut major cardiovascular events by 20%, establishing it as more than a weight drug3.
- Head-to-head data arrived in 2025. The SURMOUNT-5 trial directly compared semaglutide with tirzepatide — see semaglutide vs tirzepatide for that result.
- The frontier is moving fast: higher-dose oral semaglutide and combination drugs (like cagrilintide + semaglutide) are in active trials. We update this section as they report.
The short version
Semaglutide is an approved GLP-1 medicine that mimics a natural "fullness" hormone and is engineered to last a week. Its human evidence is extensive — STEP 1 showed ~15% average weight loss and SELECT showed a 20% cut in cardiovascular events — and it's sold as Ozempic, Wegovy, and Rybelsus. This is an educational overview, not medical advice or a judgment about whether it's right for any individual.